PE20151612A1 - Polipeptidos estabilizados del factor de crecimiento tipo insulina - Google Patents

Polipeptidos estabilizados del factor de crecimiento tipo insulina

Info

Publication number
PE20151612A1
PE20151612A1 PE2015001039A PE2015001039A PE20151612A1 PE 20151612 A1 PE20151612 A1 PE 20151612A1 PE 2015001039 A PE2015001039 A PE 2015001039A PE 2015001039 A PE2015001039 A PE 2015001039A PE 20151612 A1 PE20151612 A1 PE 20151612A1
Authority
PE
Peru
Prior art keywords
insulin
growth factor
polypeptides
type growth
stabilized polypeptides
Prior art date
Application number
PE2015001039A
Other languages
English (en)
Inventor
Mara Fornaro
Thomas Huber
Mauro Zurini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151612(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20151612A1 publication Critical patent/PE20151612A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Esta invencion esta en el campo de las modificaciones del IGF-1. En particular, se refiere a polipeptidos de IGF-1 modificados y a polipeptidos precursores de IGF-l modificados, en donde se previene la disociacion del peptido-E. La invencion tambien se refiere al uso de esos polipeptidos para el tratamiento de enfermedades y trastornos musculares
PE2015001039A 2012-12-18 2013-12-16 Polipeptidos estabilizados del factor de crecimiento tipo insulina PE20151612A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18

Publications (1)

Publication Number Publication Date
PE20151612A1 true PE20151612A1 (es) 2015-11-19

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001039A PE20151612A1 (es) 2012-12-18 2013-12-16 Polipeptidos estabilizados del factor de crecimiento tipo insulina

Country Status (37)

Country Link
US (1) US10167329B2 (es)
EP (2) EP2935320B1 (es)
JP (1) JP6499080B2 (es)
KR (1) KR102182523B1 (es)
CN (1) CN105121462B (es)
AP (1) AP2015008440A0 (es)
AU (1) AU2013365796B2 (es)
BR (1) BR112015013708B1 (es)
CA (1) CA2894976C (es)
CL (1) CL2015001708A1 (es)
CR (2) CR20200079A (es)
CU (1) CU24308B1 (es)
CY (1) CY1122309T1 (es)
DK (1) DK2935320T3 (es)
EA (1) EA034356B1 (es)
EC (1) ECSP15031046A (es)
ES (1) ES2756330T3 (es)
GT (1) GT201500168A (es)
HK (1) HK1212712A1 (es)
HR (1) HRP20191965T1 (es)
HU (1) HUE047386T2 (es)
IL (1) IL239387A0 (es)
LT (1) LT2935320T (es)
MA (1) MA38153B1 (es)
MX (1) MX363021B (es)
MY (1) MY174820A (es)
NZ (1) NZ708091A (es)
PE (1) PE20151612A1 (es)
PH (1) PH12015501271B1 (es)
PL (1) PL2935320T3 (es)
PT (1) PT2935320T (es)
RS (1) RS59545B1 (es)
SA (1) SA515360603B1 (es)
SG (1) SG11201503782PA (es)
SI (1) SI2935320T1 (es)
TN (1) TN2015000182A1 (es)
WO (1) WO2014097116A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016005716A2 (pt) * 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
SG11201807400TA (en) * 2016-03-04 2018-09-27 Shire Human Genetic Therapies Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
TW202019458A (zh) * 2018-06-27 2020-06-01 美商裘美娜治療公司 肝素相關多肽及其用途
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2234560T3 (es) 1999-01-06 2005-07-01 Genentech, Inc. Variante mutante del factor de crecimiento de tipo insulina (igf-i).
IL143834A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
PT2241575E (pt) 2005-01-07 2015-09-16 Regeneron Pharma Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的***多肽
AR061242A1 (es) 2006-06-09 2008-08-13 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada
WO2009080720A1 (en) 2007-12-21 2009-07-02 Novartis Ag Mammalian expression vector
NZ595235A (en) 2009-04-27 2013-06-28 Novartis Ag Compositions and methods for increasing muscle growth
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2014097113A2 (en) 2012-12-18 2014-06-26 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
BR112016005716A2 (pt) 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
CN105121462B (zh) 2019-08-02
CA2894976A1 (en) 2014-06-26
JP6499080B2 (ja) 2019-04-10
CA2894976C (en) 2022-10-04
NZ708091A (en) 2018-03-23
AU2013365796B2 (en) 2017-03-30
ES2756330T3 (es) 2020-04-27
MA38153A1 (fr) 2016-06-30
BR112015013708B1 (pt) 2022-10-18
CY1122309T1 (el) 2021-01-27
PL2935320T3 (pl) 2020-03-31
ECSP15031046A (es) 2019-03-29
RS59545B1 (sr) 2019-12-31
MX363021B (es) 2019-03-05
HUE047386T2 (hu) 2020-04-28
CN105121462A (zh) 2015-12-02
MX2015007932A (es) 2015-10-05
LT2935320T (lt) 2019-11-11
CU24308B1 (es) 2018-01-10
PH12015501271A1 (en) 2015-08-24
EP2935320B1 (en) 2019-08-21
MY174820A (en) 2020-05-17
GT201500168A (es) 2016-01-21
PT2935320T (pt) 2019-11-15
HK1212712A1 (zh) 2016-06-17
CR20200079A (es) 2020-03-21
SI2935320T1 (sl) 2019-12-31
KR20150095879A (ko) 2015-08-21
CL2015001708A1 (es) 2015-08-28
MA38153B1 (fr) 2018-06-29
CR20150324A (es) 2015-08-10
PH12015501271B1 (en) 2015-08-24
US20150329614A1 (en) 2015-11-19
JP2016501025A (ja) 2016-01-18
EA201591165A1 (ru) 2015-11-30
AU2013365796A1 (en) 2015-05-28
EP3626735A1 (en) 2020-03-25
HRP20191965T1 (hr) 2020-01-24
AP2015008440A0 (en) 2015-05-31
EA034356B1 (ru) 2020-01-30
EP2935320A1 (en) 2015-10-28
SA515360603B1 (ar) 2020-07-26
DK2935320T3 (da) 2019-11-18
WO2014097116A1 (en) 2014-06-26
KR102182523B1 (ko) 2020-11-25
CU20150064A7 (es) 2016-02-29
TN2015000182A1 (en) 2016-10-03
IL239387A0 (en) 2015-07-30
US10167329B2 (en) 2019-01-01
SG11201503782PA (en) 2015-06-29
BR112015013708A2 (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
PE20151612A1 (es) Polipeptidos estabilizados del factor de crecimiento tipo insulina
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
IL256004A (en) History of chloropyrazine carboxamide used in the treatment of diseases preferentially in insufficient hydration of the mucosa
SMT201700021B (it) Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
ECSP12011923A (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
PE20160787A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CU20160082A7 (es) Un proceso para la preparación de una composición de proteínas pegiladas
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
PE20150331A1 (es) Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal
UY34120A (es) Combinación sinérgica para el tratamiento de diabetes mellitus tipo 2

Legal Events

Date Code Title Description
FC Refusal